Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986506 in Advanced Clear Cell Renal Cell Carcinoma
NCT07195682Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of BMS-986506 in clear cell renal cell carcinoma (ccRCC) (7 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events at 2 years, Number of Participants With Serious Adverse Events at 2 years and 3 more. Started Jan 2026; status: recruiting.
02
Drugs
BMS-986506
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07195682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195682.